99 patients entered study and signed informed consent

45 patients discontinued before randomization

54 patients randomly assigned to study drug and received at least one dose, intent-to-treat (ITT) population

Exenatide ITT group, n=28

Discontinuations, n
Subject decision, 4
Loss of glucose control, 2

Exenatide completers, n=22
(Exenatide per protocol group, n=17)

Placebo ITT group, n=26

Discontinuations, n
Subject decision, 2
Adverse event, 1

Placebo completers, n=23
(Placebo per protocol group, n=19)